Advances in Hepatocellular and Biliary Tract Cancers Impacting Patient Outcomes

The goal of this program is to improve the knowledge and competence of learners to individualize the therapeutic management of patients with hepatobiliary cancers.

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC

Target Audience

This educational program is intended for oncologists, physician assistants, nurses, pharmacists, and other healthcare professionals involved in the care of patients with hepatobiliary cancers. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply guidelines and expert recommendations for surveillance of patients at risk of developing hepatocellular carcinoma, including the clinical application of biomarker-based surveillance
  • Integrate clinical data and consensus guidelines on the use of systemic treatment approaches into practice for patients with early-stage or intermediate-stage HCC
  • Plan evidence-based and guideline-driven individualized care for patients with advanced HCC, both in the frontline and second-line treatment settings
  • Select optimal treatment for patients with cholangiocarcinoma and other BTCs based on molecular characterization of the tumor, previous treatment, and patient characteristics and preferences
  • Identify patients with HCC who may benefit from ongoing clinical trials based on tumor characteristics, previous treatment, and patient characteristics and preferences
  • Develop strategies to identify and mitigate unique adverse events associated with novel targeted therapies in patients with hepatobiliary cancers
Additional information

Supported by an educational grant from AstraZeneca.

Course summary
Available credit: 
  • 1.75 AAPA Category 1 CME credit
  • 1.75 ACPE contact hours
  • 1.75 AMA PRA Category 1 Credit™
  • 1.75 ANCC contact hours
  • 1.75 Participation
Course opens: 
Course expires: 

Thomas A. Abrams, MD
Institute Physician
Director, Liver Tumor Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Mitesh J. Borad, MD
Professor of Medicine
Mayo Clinic College of Medicine and Science
Phoenix, Arizona

Stacey Stein, MD
Associate Professor of Medicine 
Division of Medical Oncology
Yale University
Medical Oncologist
GI Oncology
Yale Cancer Center
New Haven, Connecticut


NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 


Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below has the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Thomas A. Abrams, MD
AstraZeneca Pharmaceuticals LP: Consultant/Advisor/Speaker
Eisai Inc.: Grant/Research Support
Exelixis Inc.: Consultant/Advisor/Speaker
Servier: Consultant/Advisor/Speaker

Mitesh J. Borad, MD
AstraZeneca Pharmaceuticals LP: Grant/Research Support
Incyte Corporation: Grant/Research Support
Merck & Co., Inc.: Consultant/Advisor/Speaker
Taiho Pharmaceuticals Co., Ltd.: Grant/Research Support

Stacey Stein, MD
AstraZeneca Pharmaceuticals LP: Consultant/Advisor/Speaker
Eisai Inc.: Consultant/Advisor/Speaker
Exelixis Inc.: Consultant/Advisor/Speaker
Genentech, Inc.: Consultant/Advisor/Speaker
Imvax, Inc.: Consultant/Advisor/Speaker
Ipsen: Consultant/Advisor/Speaker
Merck & Co., Inc.: Consultant/Advisor/Speaker
QED Therapeutics: Consultant/Advisor/Speaker

NCCN and CCO Staff Disclosures

None of the planners/managers for this educational activity has relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.


In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN designates this educational activity for a maximum of 1.75 contact hours.

NCCN designates this application-based continuing education activity for 1.75 contact hours (0.175 CEUs) of continuing education credit. UAN: JA4008196-0000-23-093-H01-P

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.75 AAPA Category 1 CME credits. Approval is valid until July 21, 2024. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.75 AAPA Category 1 CME credit
  • 1.75 ACPE contact hours
  • 1.75 AMA PRA Category 1 Credit™
  • 1.75 ANCC contact hours
  • 1.75 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing